Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnover
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Alexander Lacrampe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, USA. Hauptthemen laut MEDLINE: Membrane Proteins, Nerve Tissue Proteins, Myristic Acid, Acyltransferases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIAID NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
TMEM106B, a type II transmembrane protein localized on the lysosomal membrane, has been identified as a central player in neurodegeneration and brain aging during the past decade. TMEM106B variants that increase TMEM106B expression levels are linked to several neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD). Additionally, the C-terminal lumenal fragment of TMEM106B was recently shown to form amyloid fibrils during aging and neurodegeneration. However, the mechanisms regulating TMEM106B levels are not well understood. Here we show that TMEM106B is myristoylated by NMT1/2 enzymes at its glycine 2 α-amino group and its lysine 3 ε-amino group. Myristoylation decreases TMEM106B levels by promoting its lysosomal degradation. Furthermore, we demonstrate that TMEM106B C-terminal fragments (CTFs) can be detected under physiological conditions, and the levels of CTFs are regulated by myristoylation and lysosomal activities. In addition, we show that non-myristoylated TMEM106B accumulates on the cell surface, indicating that myristoylation affects TMEM106B trafficking within the cell. Taken together, these findings suggest that TMEM106B myristoylation is an important mechanism regulating its function, trafficking, and turnover.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, USA.
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York, USA.
- Alector Inc, South San Francisco, California, USA.
- Department of Chemistry and Chemical Biology, Department of Molecular Biology and Genetics, Howard Hughes Medical Institute, Cornell University, Ithaca, New York, USA.
- Department of Molecular Biology and Genetics, Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, USA. Electronic address: fh87@cornell.edu.
Förderung
- NINDS NIH HHS
- NIAID NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Institute on Aging
Zitieren
APA
Lacrampe, A., Hou, D., Perez, I. G., Gong, B., Franco-Hernandez, N., Yee, A., Chen, W., Young-Chapon, M. A., Lin, H., & Hu, F. (2025). Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnover. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110322
Vancouver
Lacrampe A, Hou D, Perez IG, Gong B, Franco-Hernandez N, Yee A, et al. Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnover. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110322
BibTeX
@article{Lacrampe2025,
author = {Lacrampe, Alexander and Hou, Dan and Perez, Isis G and Gong, Belvin and Franco-Hernandez, Natalia and Yee, Angie and Chen, Wenzhe and Young-Chapon, Maxime Ah and Lin, Hening and Hu, Fenghua},
title = {Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnover},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110322}
}
EUVIMED